4.7 Article

Meloxicam Inhibited the Proliferation of LPS-Stimulated Bovine Endometrial Epithelial Cells Through Wnt/β-Catenin and PI3K/AKT Pathways

Journal

FRONTIERS IN VETERINARY SCIENCE
Volume 8, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fvets.2021.637707

Keywords

meloxicam; bovine endometrial epithelial cells; proliferation; lipopolysaccharide; Wnt/beta-catenin; PI3K/AKT

Funding

  1. National Natural Science Foundation of China [32072937, 31672614, 31802253]
  2. China Postdoctoral Science Foundation [2018M632398]
  3. Natural Science Foundation of Jiangsu Province [BK20160062]
  4. China Scholarship Council [201908320077]
  5. Outstanding Young Backbone Teacher Foundation of Yangzhou University
  6. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
  7. Topnotch Academic Programs Project of Jiangsu Higher Education Institutions (TAPP)

Ask authors/readers for more resources

Meloxicam has been used to relieve pain and control inflammation in cows with metritis and endometritis. The study found that meloxicam inhibited cell cycle progression and reduced cell proliferation in lipopolysaccharide-stimulated BEEC, possibly mediated by Wnt/beta-catenin and PI3K/AKT pathways.
Meloxicam is a non-steroidal anti-inflammatory drug and has been used to relieve pain and control inflammation in cows with metritis and endometritis. Meloxicam has been found to be effective in inhibiting tissue or cell growth when it is used as an anti-inflammatory therapy. However, the influence of meloxicam on bovine endometrial regeneration has not been reported. This study was to research the effect of meloxicam (0.5 and 5 mu M) on the proliferation of primary bovine endometrial epithelial cells (BEECs) stimulated by Escherichia coli lipopolysaccharide. The cell viability, cell cycle, and cell proliferation were evaluated by Cell Counting Kit-8, flow cytometry, and cell scratch test, respectively. The mRNA transcriptions of prostaglandin-endoperoxide synthase 1 (PTGS1) and PTGS2, Toll-like receptor 4, and proliferation factors were detected using quantitative reverse-transcription polymerase chain reaction. The activations of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Wnt/beta-catenin pathways were determined using western blot and immunofluorescence. As a result, co-treatment of meloxicam and lipopolysaccharide inhibited (P < 0.05) the cell cycle progression and reduced (P < 0.05) the cell healing rate and the mRNA level of proliferation factors as compared with the cells treated with lipopolysaccharide alone. Meloxicam decreased (P < 0.05) the lipopolysaccharide-induced PTGS2 gene expression. Neither lipopolysaccharide nor meloxicam changed PTGS1 mRNA abundance (P > 0.05). Meloxicam inhibited (P < 0.05) the lipopolysaccharide-activated Wnt/beta-catenin pathway by reducing (P < 0.05) the protein levels of beta-catenin, c-Myc, cyclin D1, and glycogen synthase kinase-3 beta and prevented the lipopolysaccharide-induced beta-catenin from entering the nucleus. Meloxicam suppressed (P < 0.05) the phosphorylation of PI3K and AKT. In conclusion, meloxicam alone did not influence the cell cycle progression or the cell proliferation in BEEC but caused cell cycle arrest and inhibited cell proliferation in lipopolysaccharide-stimulated BEEC. This inhibitory effect of meloxicam was probably mediated by Wnt/beta-catenin and PI3K/AKT pathways.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available